Adalimumabe no manejo da retocolite ulcerativa inespecífica: Resultados de um estudo multicêntrico observacional Brasileiro
Autor(a) principal: | |
---|---|
Data de Publicação: | 2017 |
Outros Autores: | , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNESP |
Texto Completo: | http://dx.doi.org/10.1590/s0004-2803.201700000-51 http://hdl.handle.net/11449/179347 |
Resumo: | Background – Adalimumab is a monoclonal antibody, tumor necrosis factor-alpha (TNFα) inhibitor that has efficacy for inducing and maintaining remission in moderate-to-severe ulcerative colitis. Real world studies with adalimumab in Latin American ulcerative colitis patients are scarce. Objective – To assess the clinical remission rates in induction and maintenance with adalimumab therapy in ulcerative colitis. Methods – Observational, multicenter and retrospective study on a case series of patients with moderate-to-severe ulcerative colitis under adalimumab therapy. The variables analyzed were: demographic data, previous infliximab status, concomitant drugs, the Montreal Classification, disease activity (Mayo score) at weeks 0, 8, 26 and 52, or until the last follow-up. Clinical remission was defined as a partial Mayo score ≤2 and Last observation carried forward (LOCF) and Non responder imputation (NRI) analysis were used. Results – Thirty-six patients were included in the study. With LOCF analysis, remission rates at weeks 8, 26 e 52 were of 41.7%, 47.2% and 47.2%, respectively. With NRI analysis, remission rates at weeks 8, 26 and 52 were of 41.7%, 41.7% and 27.8%, respectively. Conclusion – Adalimumab was effective in the treatment of moderate-to-severe ulcerative colitis. Clinical remission was observed in approximately 40% of the patients at weeks 8 and 26, and in almost a quarter of the patients after 1 year of follow up. |
id |
UNSP_90de964badbded39649dc77427e2e868 |
---|---|
oai_identifier_str |
oai:repositorio.unesp.br:11449/179347 |
network_acronym_str |
UNSP |
network_name_str |
Repositório Institucional da UNESP |
repository_id_str |
2946 |
spelling |
Adalimumabe no manejo da retocolite ulcerativa inespecífica: Resultados de um estudo multicêntrico observacional BrasileiroAdalimumab for ulcerative colitis: Results of a Brazilian multicenter observational studyAdalimumabInflammatory bowel diseasesProctocolitisUlcerative colitisBackground – Adalimumab is a monoclonal antibody, tumor necrosis factor-alpha (TNFα) inhibitor that has efficacy for inducing and maintaining remission in moderate-to-severe ulcerative colitis. Real world studies with adalimumab in Latin American ulcerative colitis patients are scarce. Objective – To assess the clinical remission rates in induction and maintenance with adalimumab therapy in ulcerative colitis. Methods – Observational, multicenter and retrospective study on a case series of patients with moderate-to-severe ulcerative colitis under adalimumab therapy. The variables analyzed were: demographic data, previous infliximab status, concomitant drugs, the Montreal Classification, disease activity (Mayo score) at weeks 0, 8, 26 and 52, or until the last follow-up. Clinical remission was defined as a partial Mayo score ≤2 and Last observation carried forward (LOCF) and Non responder imputation (NRI) analysis were used. Results – Thirty-six patients were included in the study. With LOCF analysis, remission rates at weeks 8, 26 e 52 were of 41.7%, 47.2% and 47.2%, respectively. With NRI analysis, remission rates at weeks 8, 26 and 52 were of 41.7%, 41.7% and 27.8%, respectively. Conclusion – Adalimumab was effective in the treatment of moderate-to-severe ulcerative colitis. Clinical remission was observed in approximately 40% of the patients at weeks 8 and 26, and in almost a quarter of the patients after 1 year of follow up.Unidade de Cirurgia Colorretal Hospital Universitário Cajuru PUCPRServiço de Gastroenterologia da FMUSPServiço de Gastroenterologia do Hospital Clementino Fraga Filho UFRJClínica GastrosaúdeClínica ESADIServiço de Gastroenterologia Hospital Nossa Senhora das GraçasDepartamento de Cirurgia Digestiva UNESPServiço de Gastroenterologia UNESPDisciplina de Bioestatística PUCPRDepartamento de Cirurgia Digestiva UNESPServiço de Gastroenterologia UNESPPUCPRUniversidade de São Paulo (USP)Universidade Federal do Rio de Janeiro (UFRJ)Clínica GastrosaúdeClínica ESADIHospital Nossa Senhora das GraçasUniversidade Estadual Paulista (Unesp)Zacharias, PatríciaDamião, Aderson Omar Mourão CintraMoraes, Antonio CarlosTeixeira, Fábio VieiraLudvig, Juliano CoelhoNones, Rodrigo BremerSaad-Hossne, Rogerio [UNESP]Sassaki, Ligia Yukie [UNESP]da Silva, Rosemary Pereira Lino [UNESP]Facchin, LuizaOlandoski, MarciaKotze, Paulo Gustavo2018-12-11T17:34:49Z2018-12-11T17:34:49Z2017-10-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article321-327application/pdfhttp://dx.doi.org/10.1590/s0004-2803.201700000-51Arquivos de Gastroenterologia, v. 54, n. 4, p. 321-327, 2017.1678-42190004-2803http://hdl.handle.net/11449/17934710.1590/s0004-2803.201700000-51S0004-280320170004003212-s2.0-85033588876S0004-28032017000400321.pdf4734747821898178Scopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengArquivos de Gastroenterologia0,396info:eu-repo/semantics/openAccess2024-08-14T14:18:41Zoai:repositorio.unesp.br:11449/179347Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-14T14:18:41Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false |
dc.title.none.fl_str_mv |
Adalimumabe no manejo da retocolite ulcerativa inespecífica: Resultados de um estudo multicêntrico observacional Brasileiro Adalimumab for ulcerative colitis: Results of a Brazilian multicenter observational study |
title |
Adalimumabe no manejo da retocolite ulcerativa inespecífica: Resultados de um estudo multicêntrico observacional Brasileiro |
spellingShingle |
Adalimumabe no manejo da retocolite ulcerativa inespecífica: Resultados de um estudo multicêntrico observacional Brasileiro Zacharias, Patrícia Adalimumab Inflammatory bowel diseases Proctocolitis Ulcerative colitis |
title_short |
Adalimumabe no manejo da retocolite ulcerativa inespecífica: Resultados de um estudo multicêntrico observacional Brasileiro |
title_full |
Adalimumabe no manejo da retocolite ulcerativa inespecífica: Resultados de um estudo multicêntrico observacional Brasileiro |
title_fullStr |
Adalimumabe no manejo da retocolite ulcerativa inespecífica: Resultados de um estudo multicêntrico observacional Brasileiro |
title_full_unstemmed |
Adalimumabe no manejo da retocolite ulcerativa inespecífica: Resultados de um estudo multicêntrico observacional Brasileiro |
title_sort |
Adalimumabe no manejo da retocolite ulcerativa inespecífica: Resultados de um estudo multicêntrico observacional Brasileiro |
author |
Zacharias, Patrícia |
author_facet |
Zacharias, Patrícia Damião, Aderson Omar Mourão Cintra Moraes, Antonio Carlos Teixeira, Fábio Vieira Ludvig, Juliano Coelho Nones, Rodrigo Bremer Saad-Hossne, Rogerio [UNESP] Sassaki, Ligia Yukie [UNESP] da Silva, Rosemary Pereira Lino [UNESP] Facchin, Luiza Olandoski, Marcia Kotze, Paulo Gustavo |
author_role |
author |
author2 |
Damião, Aderson Omar Mourão Cintra Moraes, Antonio Carlos Teixeira, Fábio Vieira Ludvig, Juliano Coelho Nones, Rodrigo Bremer Saad-Hossne, Rogerio [UNESP] Sassaki, Ligia Yukie [UNESP] da Silva, Rosemary Pereira Lino [UNESP] Facchin, Luiza Olandoski, Marcia Kotze, Paulo Gustavo |
author2_role |
author author author author author author author author author author author |
dc.contributor.none.fl_str_mv |
PUCPR Universidade de São Paulo (USP) Universidade Federal do Rio de Janeiro (UFRJ) Clínica Gastrosaúde Clínica ESADI Hospital Nossa Senhora das Graças Universidade Estadual Paulista (Unesp) |
dc.contributor.author.fl_str_mv |
Zacharias, Patrícia Damião, Aderson Omar Mourão Cintra Moraes, Antonio Carlos Teixeira, Fábio Vieira Ludvig, Juliano Coelho Nones, Rodrigo Bremer Saad-Hossne, Rogerio [UNESP] Sassaki, Ligia Yukie [UNESP] da Silva, Rosemary Pereira Lino [UNESP] Facchin, Luiza Olandoski, Marcia Kotze, Paulo Gustavo |
dc.subject.por.fl_str_mv |
Adalimumab Inflammatory bowel diseases Proctocolitis Ulcerative colitis |
topic |
Adalimumab Inflammatory bowel diseases Proctocolitis Ulcerative colitis |
description |
Background – Adalimumab is a monoclonal antibody, tumor necrosis factor-alpha (TNFα) inhibitor that has efficacy for inducing and maintaining remission in moderate-to-severe ulcerative colitis. Real world studies with adalimumab in Latin American ulcerative colitis patients are scarce. Objective – To assess the clinical remission rates in induction and maintenance with adalimumab therapy in ulcerative colitis. Methods – Observational, multicenter and retrospective study on a case series of patients with moderate-to-severe ulcerative colitis under adalimumab therapy. The variables analyzed were: demographic data, previous infliximab status, concomitant drugs, the Montreal Classification, disease activity (Mayo score) at weeks 0, 8, 26 and 52, or until the last follow-up. Clinical remission was defined as a partial Mayo score ≤2 and Last observation carried forward (LOCF) and Non responder imputation (NRI) analysis were used. Results – Thirty-six patients were included in the study. With LOCF analysis, remission rates at weeks 8, 26 e 52 were of 41.7%, 47.2% and 47.2%, respectively. With NRI analysis, remission rates at weeks 8, 26 and 52 were of 41.7%, 41.7% and 27.8%, respectively. Conclusion – Adalimumab was effective in the treatment of moderate-to-severe ulcerative colitis. Clinical remission was observed in approximately 40% of the patients at weeks 8 and 26, and in almost a quarter of the patients after 1 year of follow up. |
publishDate |
2017 |
dc.date.none.fl_str_mv |
2017-10-01 2018-12-11T17:34:49Z 2018-12-11T17:34:49Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1590/s0004-2803.201700000-51 Arquivos de Gastroenterologia, v. 54, n. 4, p. 321-327, 2017. 1678-4219 0004-2803 http://hdl.handle.net/11449/179347 10.1590/s0004-2803.201700000-51 S0004-28032017000400321 2-s2.0-85033588876 S0004-28032017000400321.pdf 4734747821898178 |
url |
http://dx.doi.org/10.1590/s0004-2803.201700000-51 http://hdl.handle.net/11449/179347 |
identifier_str_mv |
Arquivos de Gastroenterologia, v. 54, n. 4, p. 321-327, 2017. 1678-4219 0004-2803 10.1590/s0004-2803.201700000-51 S0004-28032017000400321 2-s2.0-85033588876 S0004-28032017000400321.pdf 4734747821898178 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Arquivos de Gastroenterologia 0,396 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
321-327 application/pdf |
dc.source.none.fl_str_mv |
Scopus reponame:Repositório Institucional da UNESP instname:Universidade Estadual Paulista (UNESP) instacron:UNESP |
instname_str |
Universidade Estadual Paulista (UNESP) |
instacron_str |
UNESP |
institution |
UNESP |
reponame_str |
Repositório Institucional da UNESP |
collection |
Repositório Institucional da UNESP |
repository.name.fl_str_mv |
Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP) |
repository.mail.fl_str_mv |
|
_version_ |
1808128130064318464 |